New real-world data elevating patient perspectives highlight the need for scientific advancement in maternal fetal immunology at ISUOG 2025

Patients share experiences of confusion, fear and fragmented care in managing pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN) or fetal neonatal alloimmune thrombocytopenia (FNAIT) under current standard of care These patient perspectives highlight the gap that remains for treatments that address the significant unmet need in life-threatening immune-mediated conditions during pregnancy The Phase 3 AZALEA, FREESIA-1 and FREESIA-3 clinical studies of nipocalimab, an investigational FcRn blocker, are enrolling pregnant individuals at risk for severe HDFN and FNAITWeiter zum vollständigen Artikel bei Johnson & Johnson Weiter zum vollständigen Artikel bei Johnson & Johnson